Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.400
-0.170 (-4.76%)
At close: Jul 28, 2026, 4:00 PM EDT
3.460
+0.060 (1.76%)
After-hours: Jul 28, 2026, 4:15 PM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$2,368,091
Market Cap
262.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Fate Therapeutics | 161 |
| Foghorn Therapeutics | 106 |
| Neumora Therapeutics | 92 |
| SAB Biotherapeutics | 86 |
| Agenus | 81 |
| Immuneering | 55 |
| ALX Oncology Holdings | 43 |
ELDN News
- 7 days ago - Eledon Pharmaceuticals initiated with a Buy at Rodman & Renshaw - TheFly
- 4 weeks ago - Natera, Eledon announce strategic partnership - TheFly
- 4 weeks ago - Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire
- 5 weeks ago - Eledon Pharmaceuticals Transcript: Study result - Transcripts
- 5 weeks ago - Eledon Pharmaceuticals Press release: Study result - Filings
- 5 weeks ago - Eledon Pharmaceuticals Slides: Study result - Filings
- 5 weeks ago - Eledon Pharmaceuticals announces new long-term data from BESTOW program - TheFly
- 5 weeks ago - Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - GlobeNewsWire